S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.42
+1.74
+10.43%
BCAB · BioAtla, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$1.79
-1.31
(-42.35%)
● At close: August 28 at 4:00:00 PM EDT
DAY'S RANGE
$1.79
$1.67
$2.06
52-WEEK RANGE
$1.79
$1.07
$71.50
What's happening
- BCAB is down 42.35% today, trading at $1.79. — Live quote
- It's trading within 3% of its 52-week low ($1.07). (Finnhub fundamentals)
- Volume today (9,068) is well below its 3-month average of 57,930. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-8.00 actual vs. $-12.24 estimated (+34.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BCAB
-95.38%
vs S&P 500
-107.78%
1-YEAR RETURN
BCAB
-96.84%
vs S&P 500
-112.21%
6-MONTH RETURN
BCAB
-70.92%
3-MONTH RETURN
BCAB
-64.59%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-01-26 (Q4 2025)
$-8.00
Est. $-12.24
BEAT +34.6%
2025-10-26 (Q3 2025)
$-13.50
Est. $-15.13
BEAT +10.8%
2025-07-26 (Q2 2025)
$-16.00
Est. $-17.21
BEAT +7.0%
2025-04-26 (Q1 2025)
$-13.00
Est. $-17.68
BEAT +26.5%
Valuation Measures & Ratios
Enterprise Value4$671.9K
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)0.26
Price / Book737.03
EV4 / Revenue0.08
EV4 / EBITDA—
Profit Margin-109.79%
Operating Margin-110.99%
Return on Equity (ROE8)-357.92%
Return on Assets (ROA9)-263.17%
Avg Volume (3M)57,930
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.9M | $12.3M | $2.00B | $23.0M | $20.1M |
| P/E | -0.17 | -0.22 | -33.08 | -0.35 | -0.29 |
| Price/Book | -0.19 | -0.33 | -63.98 | -1.37 | 36.77 |
| EV/EBITDA | -0.13 | -0.18 | -32.77 | — | — |
| ROE | 111.44% | 150.55% | 193.39% | 392.37% | -12838.39% |
| ROA | -424.79% | -655.70% | -379.74% | -242.19% | -183.41% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short75,558
Change from Prior Settlement-19.67%
% of Float—
Days to Cover (Short Ratio)1.38
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -17.4% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -109.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -96.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BCAB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | $227.0K | -$9.3M | -$13.8M | -$18.6M | -$17.6M | -$11.3M | -$22.0M | -$24.5M |
| Net income | $452.0K | -$6.3M | -$15.8M | -$18.7M | -$15.3M | -$10.6M | -$21.1M | -$23.2M |
| EPS (diluted) | $0.27 | $-4.22 | $-0.27 | $-15.99 | $-13.16 | $-0.22 | $-0.44 | $-0.48 |
| EPS (basic) | $0.27 | $-4.22 | $-0.27 | $-15.99 | $-13.16 | $-0.22 | $-0.44 | $-0.48 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $9.5M | $8.6M | $13.8M | $15.9M | $27.1M | $38.3M | $52.4M | $62.2M |
| Total liabilities | $45.7M | $45.9M | $50.0M | $47.1M | $43.9M | $37.7M | $38.2M | $39.3M |
| Stockholders' equity | -$36.2M | -$37.3M | -$36.2M | -$31.2M | -$16.7M | $547.0K | $14.3M | $23.0M |
| Total current assets | $4.3M | $3.1M | $8.0M | $9.7M | $20.6M | $37.5M | $51.2M | $60.6M |
| Total current liabilities | $21.0M | $20.7M | $21.9M | $18.0M | $16.6M | $16.0M | $14.5M | $19.5M |
| Cash & equivalents | $1.5M | $2.0M | $7.1M | $8.3M | $18.2M | $32.4M | $49.0M | $56.5M |
| Accounts receivable | $2.0M | — | $0 | — | — | — | — | — |
| Property, plant & equipment | $0 | $0 | $120.0K | $324.0K | $380.0K | $495.0K | $678.0K | $906.0K |
| Other non-current assets | $163.0K | $163.0K | $163.0K | $163.0K | $163.0K | — | $0 | $0 |
| Accounts payable | $12.7M | $12.1M | $8.2M | $5.9M | $4.6M | $4.7M | $1.9M | $2.9M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K |
| Retained earnings | -$551.5M | -$552.0M | -$545.6M | -$535.9M | -$520.1M | -$501.4M | -$486.0M | -$471.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$419.0K | -$5.3M | -$7.9M | -$9.9M | -$14.1M | -$16.3M | -$16.8M | -$5.1M |
| Investing cash flow | — | — | — | — | — | $0 | $0 | $0 |
| Financing cash flow | $2.0K | $110.0K | $6.7M | -$6.0K | -$36.0K | -$395.0K | $9.3M | -$14.0K |
| Depreciation & amortization | $0 | $120.0K | $19.0K | $56.0K | $115.0K | $183.0K | $228.0K | $228.0K |
| Share-based compensation | $619.0K | $956.0K | $3.8M | $1.3M | $1.4M | $1.6M | $6.6M | $2.2M |
| Deferred income taxes | — | — | $0 | — | — | — | — | — |
| Change in accounts receivable | $2.0M | — | — | — | $0 | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300.0K |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M |
| EPS (diluted) | $-1.01 | $-1.44 | $-2.58 | $-2.74 | $-2.76 |
| EPS (basic) | $-1.01 | $-1.44 | $-2.58 | $-2.74 | $-2.76 |
| Operating margin | — | — | — | — | -$32.1K |
| Net margin | — | — | — | — | -$31.8K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M |
| Stockholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M |
| Total current assets | $8.0M | $51.2M | $116.4M | $220.4M | $247.3M |
| Total current liabilities | $21.9M | $14.5M | $28.3M | $23.1M | $19.8M |
| Cash & equivalents | $7.1M | $49.0M | $111.5M | $215.5M | $245.0M |
| Property, plant & equipment | $120.0K | $678.0K | $1.6M | $2.7M | $3.7M |
| Other non-current assets | $163.0K | $0 | $154.0K | $154.0K | $154.0K |
| Accounts payable | $8.2M | $1.9M | $3.8M | $4.2M | $1.2M |
| Deferred revenue (current) | — | — | — | — | $0 |
| Common stock & paid-in capital | $6.0K | $6.0K | $5.0K | $5.0K | $4.0K |
| Retained earnings | -$545.6M | -$486.0M | -$416.3M | -$292.8M | -$186.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M |
| Investing cash flow | — | $0 | -$98.0K | -$265.0K | -$924.0K |
| Financing cash flow | $6.3M | $9.5M | $77.0K | $61.2M | $69.5M |
| Depreciation & amortization | $373.0K | $925.0K | $1.2M | $1.2M | $1.3M |
| Share-based compensation | $5.4M | $8.9M | $13.5M | $14.6M | $25.1M |
| Deferred income taxes | $0 | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BCAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-18 to 2026-08-31
Recent transactions
- Most recent: Sievers Eric (Chief Medical Officer) — Tax withholding of 134 shares on 2026-08-31.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Sievers Eric | Chief Medical Officer | Tax withholding | 2026-08-31 | 134 |
| SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 2026-08-31 | 259 |
| Vasquez Christian | Chief Financial Officer | Tax withholding | 2026-08-31 | 71 |
| WALDRON RICHARD A | Former Chief Financial Officer | Tax withholding | 2026-02-28 | 2,729 |
| Moran Susan | Reporting person | Grant / award | 2025-06-18 | 23,500 |
| Williams Eddie | Reporting person | Grant / award | 2025-06-18 | 23,500 |
| STEINMAN LAWRENCE | Reporting person | Grant / award | 2025-06-18 | 23,500 |
| GRAY MARY ANN | Reporting person | Grant / award | 2025-06-18 | 23,500 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Sievers Eric | Chief Medical Officer | Tax withholding | 134 | $1.69 |
| 2026-08-31 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 259 | $1.69 |
| 2026-08-31 | Vasquez Christian | Chief Financial Officer | Tax withholding | 71 | $1.69 |
| 2026-05-31 | Vasquez Christian | Chief Financial Officer | Tax withholding | 82 | $3.93 |
| 2026-05-31 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 259 | $3.93 |
| 2026-05-31 | Sievers Eric | Chief Medical Officer | Tax withholding | 134 | $3.93 |
| 2026-03-12 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 639 | $0.17 |
| 2026-03-11 | Vasquez Christian | Chief Financial Officer | Tax withholding | 175 | $0.17 |
| 2026-03-11 | Sievers Eric | Chief Medical Officer | Tax withholding | 360 | $0.17 |
| 2026-03-11 | SHORT JAY M PHD | Chief Executive Officer | Grant / award | 430,000 | $0.00 |
| 2026-03-10 | Sievers Eric | Chief Medical Officer | Grant / award | 240,000 | $0.00 |
| 2026-03-10 | Vasquez Christian | Chief Financial Officer | Grant / award | 240,000 | $0.00 |
| 2026-02-28 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 7,728 | $0.25 |
| 2026-02-28 | Vasquez Christian | Chief Financial Officer | Tax withholding | 1,802 | $0.25 |
| 2026-02-28 | WALDRON RICHARD A | Former Chief Financial Officer | Tax withholding | 2,729 | $0.25 |
| 2026-02-28 | Sievers Eric | Chief Medical Officer | Tax withholding | 3,140 | $0.25 |
| 2025-11-30 | WALDRON RICHARD A | Chief Financial Officer | Tax withholding | 2,371 | $0.90 |
| 2025-11-30 | Sievers Eric | Chief Medical Officer | Tax withholding | 2,729 | $0.90 |
| 2025-11-30 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 6,347 | $0.90 |
| 2025-11-30 | Vasquez Christian | See Remarks | Tax withholding | 1,566 | $0.90 |
| 2025-08-31 | SHORT JAY M PHD | Chief Executive Officer | Tax withholding | 6,347 | $0.46 |
| 2025-08-31 | Vasquez Christian | See Remarks | Tax withholding | 1,566 | $0.46 |
| 2025-08-31 | Sievers Eric | Chief Medical Officer | Tax withholding | 2,729 | $0.46 |
| 2025-08-31 | WALDRON RICHARD A | Chief Financial Officer | Tax withholding | 2,371 | $0.46 |
| 2025-06-18 | Moran Susan | Reporting person | Grant / award | 23,500 | $0.00 |
| 2025-06-18 | Williams Eddie | Reporting person | Grant / award | 23,500 | $0.00 |
| 2025-06-18 | STEINMAN LAWRENCE | Reporting person | Grant / award | 23,500 | $0.00 |
| 2025-06-18 | GRAY MARY ANN | Reporting person | Grant / award | 23,500 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-16 | 8-K | 2026-07-16 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-11 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-12 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-03-11 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about BCAB (BioAtla, Inc.). Links open the publisher — we don’t host full articles.
-
BCAB S-1 & SEC Filings
Yahoo Finance · 2026-10-20 -
BioAtla Replaces $15M Yorkville Facility With $40M Standby Equity Purchase Agreement
Minichart · 2026-10-20 -
BioAtla Secures $40 Million Standby Equity Purchase Facility With Yorkville for 36 Months
TradingView · 2026-10-20 -
BioAtla, Inc. (BCAB) Stock Price & News
Syfe · 2026-10-16 -
BioAtla Q3 2026 Earnings Date and Estimates
MarketBeat · 2026-10-16 -
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Yahoo Finance · 2026-05-18 -
BioAtla GAAP EPS of -$0.16, revenue of $2M
Seeking Alpha · 2026-03-31 -
BioAtla Announces Share Consolidation
Yahoo Finance · 2026-03-31
No headlines in this category right now — try “All”.